Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (517)	7/27/2019 11:06:25 AM
From: BulbaMan	Read Replies (1) of 684

Thanks for posting the list! I wonder if it would be useful to check for the ages of the CEOs of the biotechs selling below cash. I’m assuming that the cash rich biotechs are pipeline poor. Also that an elderly CEO would be motivated to retire on a “high” (or at least “higher”) note rather than just slowly burn away the company cash (or get pushed out by disgruntled investors). So, prior to retiring, they would actively either: 1) Seek to sell the company at a premium, even if only at its cash value. 2) Seek to merge with another biotech that’s cash poor but pipeline rich. I know I’m not the first to think of CEO age as important but have never seen a study as it relates to cash rich biotechs. The subject pool does appear large enough for such a study to make sense. Peace & good health, Bulba

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next